768 related articles for article (PubMed ID: 26858331)
1. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
2. Molecular Staging of Sentinel Lymph Nodes Identifies Melanoma Patients at Increased Risk of Nodal Recurrence.
Kimbrough CW; Egger ME; McMasters KM; Stromberg AJ; Martin RC; Philips P; Scoggins CR
J Am Coll Surg; 2016 Apr; 222(4):357-63. PubMed ID: 26875070
[TBL] [Abstract][Full Text] [Related]
3. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
4. The Sunbelt Melanoma Trial.
Egger ME; Scoggins CR; McMasters KM
Ann Surg Oncol; 2020 Jan; 27(1):28-34. PubMed ID: 31529312
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from the Sunbelt Melanoma Trial.
McMasters KM; Noyes RD; Reintgen DS; Goydos JS; Beitsch PD; Davidson BS; Sussman JJ; Gershenwald JE; Ross MI;
J Surg Oncol; 2004 Jul; 86(4):212-23. PubMed ID: 15221928
[TBL] [Abstract][Full Text] [Related]
7. Melanoma Patient-Reported Quality of Life Outcomes Following Sentinel Lymph Node Biopsy, Completion Lymphadenectomy, and Adjuvant Interferon: Results from the Sunbelt Melanoma Trial.
Egger ME; Kimbrough CW; Stromberg AJ; Quillo AR; Martin RC; Scoggins CR; McMasters KM
Ann Surg Oncol; 2016 Mar; 23(3):1019-25. PubMed ID: 26744107
[TBL] [Abstract][Full Text] [Related]
8. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer NH; Berking C; Sunderkötter C; Kaatz M; Schatton K; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Verver D; Martus P; Garbe C;
J Clin Oncol; 2019 Nov; 37(32):3000-3008. PubMed ID: 31557067
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
10. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
11. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
12. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
Fujisawa Y; Otsuka F;
Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
[TBL] [Abstract][Full Text] [Related]
13. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma.
Manca G; Romanini A; Pellegrino D; Borsò E; Rondini M; Orlandini C; Zucchi V; Pasqualetti F; Mariani G
J Nucl Med; 2008 Nov; 49(11):1769-75. PubMed ID: 18927334
[TBL] [Abstract][Full Text] [Related]
14. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
Broman KK; Hughes TM; Dossett LA; Sun J; Carr MJ; Kirichenko DA; Sharma A; Bartlett EK; Nijhuis AA; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma J; Deneve JL; Fleming MD; Perez M; Baecher K; Lowe M; Bagge RO; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras RM; Teras J; Farrow NE; Beasley GM; Hui JY; Been L; Kruijff S; Boulware D; Sarnaik AA; Sondak VK; Zager JS;
J Am Coll Surg; 2021 Apr; 232(4):424-431. PubMed ID: 33316427
[TBL] [Abstract][Full Text] [Related]
16. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
Wong SL; Morton DL; Thompson JF; Gershenwald JE; Leong SP; Reintgen DS; Gutman H; Sabel MS; Carlson GW; McMasters KM; Tyler DS; Goydos JS; Eggermont AM; Nieweg OE; Cosimi AB; Riker AI; G Coit D
Ann Surg Oncol; 2006 Jun; 13(6):809-16. PubMed ID: 16604476
[TBL] [Abstract][Full Text] [Related]
17. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK; Hughes T; Dossett L; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma JM; Deneve JL; Fleming MD; Perez MC; Lowe MC; Olofsson Bagge R; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley G; Hui JYC; Been L; Kruijff S; Kim Y; Naqvi SMH; Sarnaik AA; Sondak VK; Zager JS
Cancer; 2021 Jul; 127(13):2251-2261. PubMed ID: 33826754
[TBL] [Abstract][Full Text] [Related]
20. Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival.
Woeste MR; McMasters KM; Egger ME
J Am Coll Surg; 2021 Apr; 232(4):517-524.e1. PubMed ID: 33316426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
